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Conclusion: An extensive inﬂuenza surveillance program
in Asia can document virus movement and genetic changes,
and is well positioned to provide assistance during pan-
demics and prevention efforts.
doi:10.1016/j.ijid.2010.02.2206
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H1N1 experience at the Institute for Infectious Diseases
Emilio Ribas, Sao Paulo, Brazil. The role of a travel clinic
as sentinel for emerging diseases
J. Alves, C.E. Guarnieri, T.S. Chaves ∗
Institute for Infectious Diseases Emilio Ribas, Sao Paulo,
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Background: According to WHO ﬁgures, by November 8
more than 503,536 cases of pandemic inﬂuenza had been
conﬁrmed and more than 6,260 deaths had been reported.
Most cases came from the Americas which also presented
the highest number of deaths. South America was severely
affected by the transmission of H1N1 and big efforts made to
control its dissemination and assist severe cases. Before July
16, when sustained transmission of pandemic inﬂuenza H1N1
was recognized in Brazil, most cases were travel related. By
late November, 22,565 cases had been reported in the coun-
try with a total of 1,528 deaths. The Institute for Infectious
Diseases Emilio Ribas (IIDER), a reference hospital for infec-
tious diseases in Sao Paulo city, was responsible for reporting
a signiﬁcant number of the entire state’s cases. As H1N1
was initially related to travelers, a number of patients were
referred to the clinic to be followed.
Methods: To evaluate the role of the travel clinic during
the ﬁrst months of the pandemic, we analyzed 53 report
care forms, broken down by gender, age, symptoms, history
of travel, diagnosis and treatment.
Results: Of the 53 patients evaluated, 21 were male
(39.6%) and 32 female (60.4%). The mean age was 38.7
and the most common symptoms were cough (90.5%), fever
(83%), headache (79%), coryza (64.1%), myalgia (73.5),
shortness of breath (49%) and diarrhea (16.9%). Oseltamivir
was prescribed to 35 (66%) of all patients. H1N1 was con-
ﬁrmed in 18 patients and Sazonal Inﬂuenza was isolated in
6 patients. Out of 17 patients who had traveled internation-
ally, only 3 tested positive for H1N1 and they had come from
Argentina (2) and Mexico (1).
Conclusion: Since the begining of the Inluenza pandemic,
IIDER had reported a total of 1,924 ﬂu-like cases by October
1, 2009. Because H1N1 transmission was initially associated
with travelers, travel clinics were able to provide ﬁrst warn-
ing. In our report, we include the ﬁrst case of H1N1 infection
in Sao Paulo city, a patient returning from Mexico who pre-
sented symptoms 2 days before the WHO global alert, which
demonstrates the high sensitivity of post-travel evaluations
in a pandemic scenario.
doi:10.1016/j.ijid.2010.02.2207
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Background: Since the H1N1 vaccine approval on October
1, 2009 in Canada, the largest vaccination program in the
ountry’s history has been rolled out. This work contributes
nformed estimates to the current debate about the pan-
emic (H1N1) 2009 mass immunization program’s economic
erits.
Methods: We performed a cost-utility analysis of the
H1N1) 2009 mass immunization program in Ontario,
anada’s most populous province. We utilize a previ-
usly developed model to simulate the current pandemic
nﬂuenza (H1N1) outbreak in Ontario to compare no inter-
ention to mass immunization of 10% of the population
er week, starting 40 days into the pandemic and last-
ng until 30% vaccine coverage is reached. Data for health
are resource use (ofﬁce visits, emergency department vis-
ts, hospitalizations, intensive care unit admissions, use of
xtracorporeal membrane oxygenation (ECMO)) and deaths
ere based on pandemic (H1N1) surveillance data in Ontario
nd Australia, and Ontario administrative data. Program
nd other costs were drawn from Ontario sources (Ontario
ealth Insurance Plan (OHIP), Ontario Case Costing Initiative
OCCI)). Utility weights were obtained from the literature
nd annualized. Years of life lost were calculated using
verage life expectancy adjusted for quality of life. Main
utcome measures were quality adjusted life-years (QALYs),
osts in 2009 Canadian dollars, and cost per QALY gained.
Results: Ontario’s H1N1 immunization program is esti-
ated to cost $118 million ($30 per person vaccinated).
mmunizing 30% of the population prevents approximately
.4 million cases, 850 hospitalizations and 35 deaths. This
educes healthcare cost due to illness from $154 million to
77 million and is associated with 24,864 additional quality-
djusted life-years for the population. The incremental
ost-effectiveness ratio (ICER) is $1,645 per QALY gained.
esults are sensitive to immunization program effectiveness
nd cost. In all sensitivity analyses the ICER remains well
elow established thresholds, which determine the cost-
ffectiveness of a program.
Conclusion: The pandemic (H1N1) 2009 mass immu-
ization program in Ontario is highly costeffective under
onservative assumptions on health care resource use, costs,
nd mortality. This conclusion is supported by extensive
ensitivity analyses and is consistent with the economic
ttractiveness demonstrated for seasonal inﬂuenza pro-
rams.
oi:10.1016/j.ijid.2010.02.2208
